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Introduction: European countries need to learn from each other to address unsustainable increases 
in pharmaceutical expenditures. Objective: To assess the influence of the many supply and 
demand-side initiatives introduced across Europe to enhance prescribing efficiency in ambulatory 
care. As a result provide future guidance to countries. Methods: Cross national retrospective 
observational study of utilization (DDDs – defined daily doses) and expenditure (Euros and local 
currency) of proton pump inhibitors (PPIs) and statins among 19 European countries and regions 
principally from 2001 to 2007. Demand-side measures categorized under the “4Es” – education 
engineering, economics, and enforcement. Results: Instigating supply side initiatives to lower the 
price of generics combined with demand-side measures to enhance their prescribing is important 
to maximize prescribing efficiency. Just addressing one component will limit potential efficiency 
gains. The influence of demand-side reforms appears additive, with multiple initiatives typically 
having a greater influence on increasing prescribing efficiency than single measures apart from 
potentially “enforcement.” There are also appreciable differences in expenditure (€/1000 inhabitants/
year) between countries. Countries that have not introduced multiple demand side measures to 
counteract commercial pressures to enhance the prescribing of generics have seen considerably 
higher expenditures than those that have instigated a range of measures. Conclusions: There are 
considerable opportunities for European countries to enhance their prescribing efficiency, with 
countries already learning from each other. The 4E methodology allows European countries to 
concisely capture the range of current demand-side measures and plan for the future knowing 
that initiatives can be additive to further enhance their prescribing efficiency.
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products likely to lose their patents between 2008 and 2013 (Frank, 
2007; Jack, 2008). The initiatives are similar and include defined 
criteria for granting substitutability status for generics, publishing 
lists of substitutable and non-substitutable products, not reimburs-
ing generics where there are concerns with their quality, physician 
and patient education, encouraging International non-proprietary 
name (INN) prescribing as well as incentivizing pharmacists to 
talk with patients when substituting to allay any fears (Allenet and 
Barry, 2003; Valles et al., 2003; Kjoenniksen et al., 2006; Kopp and 
Vandevelde, 2006; Godman et al., 2008a, 2009a; Teixeira and Vieira, 
2008; Versantvoort et al., 2008; Duerden and Hughes, 2010; Sermet 
et al., 2010). These concerns though generally only apply in a limited 
number of situations (Valles et al., 2003; Kjoenniksen et al., 2006; 
Heikkilä et al., 2007; Shrank et al., 2009). As a result, there should 
be considerable opportunities for European countries to further 
enhance their prescribing efficiency without compromising care. 
This should be welcomed as further reforms are essential to main-
tain comprehensive and equitable healthcare throughout Europe as 
we are already seeing European countries experiencing difficulties 
with funding new premium priced ambulatory care drugs even 
when these are considered cost–effective. Current activities to help 
fund new innovative drugs include (Cooke et al., 2005; DoH, 2006, 
2008; Godman et al., 2009a; Krska and Godman, 2010; Wettermark 
et al., 2010b):
•	 placing	 them	on	“waiting	 lists”	until	more	 funding	becomes	
available, e.g., Lithuania
•	 funding	 a	 limited	 number	 through	 special	 programs,	 e.g.,	
“Therapeutic	Programs”	in	Poland
•	 increasing	 planning	 activities	 to	 pro-actively	 address	 poten-
tial funding concerns. This includes ascertaining the potential 
role for new treatments ahead of launch as well as identifying 
potential areas to release resources, such as current treatments 
that well soon lose their patent, to fund new innovative treat-
ments at launch, e.g., Sweden and UK. Subsequently monito-
ring prescribing of the new products against agreed guidance 
post launch
It is recognized it is difficult for countries to learn from each 
other in view of different circumstances and starting points, with 
one approach unlikely to fit all countries. In addition, prescrib-
ing behavior is complex (Grol	and	Grimshaw,	2003;	Prosser	et	al.,	
2003;	Prosser	and	Walley,	2005;	Wettermark	et	al.,	2009b). Having 
said this, there are examples of European countries learning from 
each other when considering new health reforms (Toth, 2010). 
In addition, the plethora of different measures introduced across 
Europe to enhance prescribing efficiency should stimulate debates 
within countries on additional reforms and initiatives that could 
be introduced. Coupled with this, cross national comparisons of 
drug utilization and expenditure also help identify possible addi-
tional reforms that countries could introduce through analyti-
cal studies linking datasets from different countries and regions 
and matching changes in utilization and expenditure with health 
policy initiatives.
The objectives of this paper are to assess the influence of 
the many supply and demand-side reforms and initiatives 
introduced across Europe to enhance prescribing efficiency in 
IntroductIon
Scrutiny of pharmaceutical expenditures is increasing as this is the 
fastest growing cost component in ambulatory care, with pharma-
ceutical expenditures now typically the largest cost or equal largest 
component in this sector across Europe (Ess et al., 2003; Godman 
et al., 2008a; Simoens, 2008a; Coma et al., 2009; Barry et al., 2010; 
Sermet et al., 2010).	Pharmaceutical	expenditure	is	proportionally	
higher in middle and lower income countries at between 20 and 
60% of total healthcare spending, although from a lower baseline 
(Cameron et al., 2009). The reasons for increasing expenditures 
are well known and include demographic changes, the continued 
launch of new expensive medicines, rising patient expectations and 
stricter clinical targets (Gumbs et al., 2007; Garattini et al., 2008; 
Lee and Emanuel, 2008; Barry et al., 2010). New biological drugs 
marketed at appreciably higher acquisition costs than previous 
standards provide additional impetus to this growth in expendi-
ture enhancing the scrutiny (Caroll, 2005; Barrett et al., 2006; Lee 
and Emanuel, 2008).
This unsustainable growth has resulted in increasing urgency 
among governments, health authorities and health insurance com-
panies to introduce reforms to improve prescribing efficiency for 
both new and existing drugs (Traulsen and Almarsdóttir, 2005; Toth, 
2010). Supply side reforms for existing drugs include compulsory 
price cuts, measures to lower generic prices, reference pricing in a 
class (Anatomical Therapeutic Classification Level 4 – World Health 
Organization [WHO], 2009) including voluntary reference pricing, 
as well as delisting products from the reimbursement list when they 
are considered no longer to be cost–effective versus current stand-
ards (Godman et al., 2008a,b, 2009a,b,c, 2010a; Simoens, 2008b; 
Teixeira and Vieira, 2008; Wettermark et al., 2008; Coma et al., 
2009; Elshaug et al., 2009; McGinn et al., 2010; Sermet et al., 2010). 
Demand-side reforms and initiatives for existing drugs include 
measures to enhance the prescribing and dispensing of generics. 
This includes academic detailing and prescribing guidance incor-
porating electronic prescribing support systems, prescribing targets, 
financial incentives including incentives to enhance substitution in 
pharmacies, mandatory substitution unless prohibited by govern-
ment agencies and administrative barriers to relegate the prescribing 
of patent protected products in a class or related classes to second 
line (Tilson et al., 2005; Gumbs et al., 2007; Hyde, 2007; Sakshaug 
et al., 2007; Sjöborg et al., 2007; Gouya et al., 2008; Simoens, 2008b,c; 
Godman et al., 2009a,c, 2010b; Wettermark et al., 2009a,b, 2010a; 
Krska and Godman, 2010; Martikainen et al., 2010; McGinn et al., 
2010; Sermet et al., 2010). A number of these strategies are aimed 
at counter-acting the commercial activities of pharmaceutical com-
panies, who have typically been the principal source of information 
among physicians for new drugs (Jones et al., 2001; Prosser	et	al.,	
2003;	Szecseny,	2003;	Watkins	et	al.,	2003;	Pegler	and	Underhill,	
2005). This together with the complex nature of prescribing helps 
explain why pharmaceutical companies in the UK currently invest 
over £850 mn/year in marketing activities, with similar experiences 
across Europe (Beishon et al., 2007; Godman et al., 2008b).
Alongside this, governments, health authorities and health insur-
ance agencies have instigated a range of measures to address physi-
cian and patient concerns with the effectiveness and/or side-effects 
of generics to release valuable resources. This urgency has increased 
with estimated global sales of products of $US50 bn to $US100 bn of 
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•	 Mixed	approaches	(MA)	–	typically	prescriptive	pricing	for	the	
first generic or generics; market forces after that
We acknowledge though that in some countries only branded 
generics are available. However, to reduce confusion only the term 
“generics”	will	be	used	throughout	the	paper.
Only administrative databases were used to ensure standardiza-
tion across countries. These included (100% coverage of the popu-
lation unless stated):
•	 AT	(Austria)	–	Data	Warehouse	of	the	Federation	of	Austrian	
Social Insurance Institutions (98% of the population)
•	 DE	(Germany)	–	GAMSI-Database,	i.e.,	the	GKV	Arzneimittel	
Schnell-Information, which covers all prescriptions paid by 
the Social Health Insurance Funds (SHI – approximately 90% 
of the population)
•	 EE	(Estonia)	–	Estonian	Health	Insurance	Fund
•	 ES	 (Spain	 –	 only	 Catalonia)	 –	 DMART	 (Catalan	 Health	
Service) database (all patients in Catalonia). Data only availa-
ble from 2003 onwards
•	 FI	 (Finland)	 –	 Prescription	Register	 of	 the	 Social	 Insurance	
Institution
•	 FR	 (France)	 –	Medic’am	 database	 (CNAM-TS	 database	 for	
salaried personnel covering 75% of the population)
•	 GB	 –	 Eng	 (England)	 –	 Information	 Centre	 for	 Health	 and	
Social Care
•	 GB	–	Scot	(Scotland)	–	Prescribing	Information	System	(PIS)	
from NHS National Services Scotland Corporate Warehouse
•	 HR	(Croatia)	–	Croatian	Institute	for	Health	Insurance
•	 IE	(Republic	of	Ireland)	–	HSE-PCRS	(GMS	Population	cove-
ring approximately 30% of the population with higher mor-
bidity than the general population reflected in consuming 
approximately 65% of total pharmaceutical expenditure)
•	 IT	(Italy)	–	OsMed	database
•	 LT	 (Lithuania)	–	Electronic	database	of	 the	National	Health	
Insurance Fund
•	 NO	(Norway)	–	Norwegian	Prescription	Database	 (NorPD).	
Expenditure data only available from 2004 onwards
ambulatory care once a decision has been made to prescribe 
a particular class of drug. Subsequently utilize the findings to 
suggest potential future initiatives that countries could con-
sider to further enhance their prescribing efficiency given 
continued resource pressures. This though acknowledging the 
 complexities involved.
MaterIals and Methods
This is a cross national retrospective observational study involving 
the analysis of reimbursed utilization and expenditure on a yearly 
basis	for	the	Proton	Pump	Inhibitors	(PPIs)	and	HMG	CoA	reduct-
ase inhibitors (statins) among European countries.
Nineteen European countries and regions took part in this study. 
These	were	Austria	(AT),	Croatia	(HR),	Estonia	(EE),	France	(FR),	
Finland (FI), Germany (DE), Italy (IT), Lithuania (LT), Norway 
(NO),	Portugal	(PT),	Poland	(PO),	Republic	of	Ireland	(IE),	Serbia	
(RS),	 Slovenia	 (SI),	 Spain	 (ES	 –	 only	 Catalonia),	 Sweden	 (SE),	
Turkey	(TR),	and	the	United	Kingdom	(GB-Eng	–	England	and	
GB-Scot – Scotland). The countries reflect differences in geogra-
phy, epidemiology, financing of healthcare, available resources for 
healthcare as well as different approaches to the pricing of gener-
ics, originators, and single sourced products (Table 1). They also 
reflect appreciable differences in the nature and extent of reforms 
and initiatives introduced to enhance the prescribing of generics. 
As a result, provide a number of exemplar initiatives and countries 
(Table A1 of Appendix).
The following definitions have been used to classify the differ-
ent pricing approaches for generics across Europe, which build on 
previous publications (Godman et al., 2010a,c):
•	 Prescriptive	 pricing	 (PP)	 –	 mandated	 price	 reductions	 for	
generics for reimbursement compared with for instance pre-
patent loss prices for the molecule
•	 Market	forces	(MF)	–	no	prescriptive	pricing	approaches;	price	
reductions left to market forces with typically patients paying 
an additional co-payment for a more expensive product inclu-
ding branded generics than the current referenced priced 
molecule
Table 1 | Characteristics of the European countries in 2008 (using published definitions for generic pricing).
 AT DE EE ES  FI FR GB –  GB –  HR IE IT LT NO PO PT RS SE SI TR 
       Eng Scot
Financing –     ü ü  ü ü  ü ü  ü  ü  ü  ü 
taxation
Financing –  ü ü ü   ü   ü   ü  ü  ü  ü  
health insurance
Generics – PP      ü       ü      ü
Generics – MF  ü  ü   ü ü      ü   ü  
Generics – MA ü  ü AC ü    ü ü ü ü   ü ü  ü 
Reference VP ü NI NI AC NI RJT RJT ü NI ü AC NI ü NI Part Only PPIs NI ü 
pricing – class 
(ATC Level 3 or 4)
Generic pricing: AC, actively considering. Reference pricing: VP, voluntary reference pricing; NI, not introduced; RJT, proposed but rejected; AC, active consideration; 
Part, partial applying to some product classes but not all.
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Utilization rates for the different molecules in each class were 
computed using Defined Daily Doses (DDDs), with utilization 
patterns in 2007 generally compared with 2001. These dates were 
chosen as typically both generic simvastatin and generic omepra-
zole became available and were reimbursed during this time period 
among Western European countries (Table 2). Simvastatin was the 
first major statin to become available as a generic in Europe with 
generally no or limited utilization of lovastatin. Omeprazole was 
the	first	PPI	to	become	available	as	a	generic.	Both	events	resulted	
in demand-side initiatives to try and enhance the prescribing of 
generics ahead of more expensive patent protected products to 
improve prescribing efficiency (Table A1 of Appendix).
The concepts of ATC classification and DDDs were developed 
to facilitate cross country comparisons in drug utilization espe-
cially where there are differences in pack sizes and available tablet 
strengths (Bergman	et	al.,	1979;	Rønning	et	al.,	2000;	Rønning, 
2002). DDDs are now internationally accepted for comparing drug 
utilization patterns across countries (Birkett, 2002; WHO, 2003; 
Walley et al., 2004a; Vlahovic´-Palcevski	et	al.,	2010). The ATC index 
from 2010 was used in this study in line with WHO recommenda-
tions (Rønning et al., 2000).
Demand-side measures, i.e., initiatives and reforms to influence 
subsequent prescribing or dispensing of generics, have been collated 
under	the	“4	Es,”	i.e.,	education,	engineering,	economics	and	enforce-
ment. This approach has been used in other settings and successfully 
adapted to healthcare to provide a concise and easily understandable 
methodology to compare and contrast the complexity and multi-
plicity of demand-side measures implemented within and between 
countries (Coma et al., 2009; Godman et al., 2009a,c; Wettermark 
et al., 2009b; McGinn et al., 2010).	Examples	of	the	“4	Es”	include:
•	 PO	(Poland)	–	National	Health	Fund	database
•	 PT	(Portugal)	–	INFARMED	(NHS)	database	(approximately	
75% of the population)
•	 RS	 (Serbia)	 –	 Republic	 of	 Serbia’s	 Health	 Insurance	 Fund	
database
•	 SE	(Sweden)	–	Apoteket	AB	(National	Corporation	of	Swedish	
Pharmacies	–	monopoly	up	to	1	January	2010)
•	 SI	 (Slovenia)	 –	 The	National	 Institute	 of	 Public	Health	 and	
Health	Insurance	Institute	Prescription	Database
•	 TR	(Turkey)	–	Social	Security	Institution	(SGK)	–	single	natio-
nal public payer purchasing approximately 95% of pharma-
ceutical expenditure in Turkey
As discussed, two classes were chosen for in-depth analysis 
of	ambulatory	care	prescribing	efficiency.	These	were	the	PPIs	–	
Anatomical Therapeutic Chemical (ATC) A02BC, and the HMG 
CoA reductase inhibitors (statins) – ATC group C10AA (WHO, 
2009). These two classes were chosen as (AFSSAPS,	2005;	MeReC	
Extra, 2006; National Institute for Health and Clinical Excellence, 
2006; Wessling and Lundin, 2006; Godman et al., 2008b, 2009a,b; 
Eriksson and Lundin, 2009; Martikainen et al., 2010; McGinn 
et al., 2010):
•	 they	are	both	commonly	prescribed	in	ambulatory	care
•	 they	also	contain	a	mixture	of	generics,	originators	and	sin-
gle sourced products in a class and many patients, if not all 
in	the	case	of	PPIs,	can	be	adequately	managed	with	generic	
products
•	 PPIs	 and	 statins	 are	 typically	 the	 subject	 of	 country	 and/or	
regional initiatives to enhance prescribing efficiency
Table 2 | Dates when generic omeprazole and generic simvastatin were first dispensed and reimbursed among European countries.
Country Year when generic omeprazole Year when generic simvastatin Comments 
 was dispensed and reimbursed was dispensed and reimbursed
AT (Austria) 2003 2002 
DE (Germany) 2002 2003 
EE (Estonia) Before 2001 2001 Reimbursement data only available from 2004
ES (Spain – Catalonia) Before 2003 Before 2003 Data only available after 2003
FI (Finland) 2002 Before 2001 Data only from 2001 to 2007
FR (France) 2004 2005 
GB – Eng (England) 2002 2003 
GB – Scot (Scotland) 2002 2003 
HR (Croatia) Before 2000 2001 Data will include 2000 to 2007
IE (Republic of Ireland) 2002 2003 
IT (Italy) 2007 2007 2008 compared with 2006 as both generic omeprazole 
   and generic simvastatin became available in 2007
LT (Lithuania) Before 2001 Before 2001 
NO (Norway) Before 2004 Before 2004 Pharmacy reimbursement data only available from 2004
PO (Poland) Before 2001 Before 2001 
PT (Portugal) Before 2001 2001 
RS (Serbia) Before 2005 Before 2005 Data only available from 2005 onwards
SE (Sweden) 2003 2003 
SI (Slovenia) Before 2001 Before 2001 
TR (Turkey) Before 2007 Before 2007 Data only available from 2007 to 2009
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Two	principal	analyses	were	undertaken	for	both	the	PPIs	and	
statins to assess overall efficiency, with criteria subsequently broken 
down into three categories. These are summarized in Table 3. The 
three cut-off points for assessing efficiency were chosen intuitively; 
however, tested among the co-authors for internal validity.
In view of the limited number of peer-reviewed publications 
documenting current reforms for the pricing of generics, as well 
as current demand-side reforms and their impact especially for the 
PPIs	and	statins	among	the	19	European	countries	and	regions	out-
side of those from a number of the co-authors, details of these were 
typically provided by the co-authors. This method was also chosen 
to add robustness and standardization to the documentation since 
many of the co-authors are involved with either implementing 
or suggesting additional reforms in their country or region. This 
especially as there have been concerns with the accuracy of some 
of the health policy information contained within some of the 
web based publications (Blaszczyk et al., 2007).
No attempt has been made to analyze the appropriateness of 
prescribing	of	either	the	PPIs	or	statins.	This	is	due	to	a	lack	of	
access to patient databases to determine the indication and/or 
doses prescribed. In addition, the main emphasis of this paper 
is regarding prescribing efficiency once a decision has been 
made	by	the	physician	to	prescribe	either	a	PPI	or	statin.	These	
issues though have been discussed in individual country publi-
cations (Coma et al., 2009; Godman et al., 2009a,b,c; McGinn 
et al., 2010).
No impact analyses have been undertaken as typically multiple 
supply and demand-side initiatives were instigated in each coun-
try during the study period and the datasets generally covered the 
whole population. In addition, the intensity of different initiatives 
may vary over time and between different regions further hindering 
the usefulness of such analyses. This is reflected in the discussion. 
No regression lines have been added to Figures 3 and 4 as each 
point represents a different country subject to different supply and 
demand-side reforms (Table A1 of Appendix).
results
Table A1 in the appendix documents the main pricing reforms for 
generics during the study period among the 19 European countries 
and regions. Table A1 also documents the nature and intensity of 
the demand-side reforms introduced to enhance prescribing effi-
ciency	principally	for	the	PPIs	and	statins	collated	under	the	“4	Es.”	
Any co-payments for the product and/or indication, in addition 
to the standard co-payment for the package, are also included in 
Table A1. This recognizes that some European countries use this 
“economic”	approach	to	influence	utilization.
Figure 1 demonstrated the influence of the various supply and 
demand-side measures (Table A1	of	Appendix)	on	PPI	prescrib-
ing efficiency among the different European countries and regions 
as measured by the rate of change in utilization (DDDs) versus 
reimbursed expenditure principally between 2001 and 2007. The 
countries have been broken down by:
•	 geography	–	into	Central	and	Eastern	European	countries	and	
the remainder, for the reasons discussed in Table 3
•	 the	different	approaches	to	pricing	of	generics	–	Prescriptive	–	
PP,	Market	Forces	–	MF,	Mixed	–	MA
•	 Educational	activities	–	includes	development	and	distribution	
of prescribing guidance right through to more intensive strate-
gies such as educational outreach visits and benchmarking of 
physician prescribing habits
•	 Engineering	 activities – includes organizational or manage-
rial interventions such as prescribing targets and compulsory 
INN prescribing as well as price: volume agreements for single 
sourced existing products
•	 Economic	 interventions	 –	 includes	 devolved	 budgets	 with	
penalties, positive and negative financial incentives, as well as 
differential patient co-payments for more expensive products 
than the current reference molecule
•	 Enforcement	–	includes regulations by law such as mandatory 
generic substitution and prescribing restrictions
Reimbursed	 expenditures	 from	 2001	 to	 2007	 were	 typically	
captured for each class to assess the influence of recent reforms 
on overall expenditure from a health authority or health insur-
ance perspective. The only exceptions were Austria, Germany and 
Norway where there are difficulties with disassociating co-payments 
from total expenditure. However, this typically represents only a 
small proportion of overall expenditure in these three countries. 
Expenditure data was collected in local currency.
Reimbursed	expenditures,	as	opposed	to	total	expenditures,	were	
chosen for the analysis as this is the actual expenditure incurred by 
health authorities or health insurance agencies reflecting the focus 
of	the	paper.	Reimbursed	expenditures	in	2007	was	subsequently	
converted to €/1000 inhabitants/year to compare expenditures 
across countries adjusted for population sizes. This includes cur-
rency conversions where pertinent to standardize the approach. 
This was based on established rates for the country; alterna-
tively an average for the year from national banks (Godman and 
Wettermark, 2009a,b). 2007 was chosen for this calculation as this 
was the latest year for comprehensive data from all countries. Again, 
expenditure/1000 inhabitants/year is the internationally accepted 
standard approach for comparing expenditures across countries. 
Exchange rates used were €1 = 0.734GB£, LTL3.453, 8.219NOK, 
3.783PLN,	79.24RSD	and	9.25SEK	(2007).
There has been no allowance for inflation in the analysis in order 
to directly compare the impact of different policies over time. In 
addition, health authorities and health insurance agencies typi-
cally refer to pre-patent loss prices when establishing reimbursed 
prices for generics especially for prescriptive pricing or mixed 
approaches to the pricing of generics (Godman et al., 2010a,c). It 
is acknowledged though that savings will be greater if inflation is 
factored in.
The data sets collected to compare prescribing efficiency for the 
PPIs	and	statins	among	the	European	countries	included:
•	 Total	DDDs	2001	and	2007
•	 DDDs/1000	inhabitants/day	(DDDs/TID)
•	 Reimbursed	expenditure	in	2001	and	2007
•	 €/1000 inhabitants/year in 2007
•	 Principal	reforms	to	lower	the	price	of	generics
•	 Principal	demand-side	reforms	to	enhance	the	prescribing	of	
generic	 PPIs	 and	 statins	 compared	with	 single	 sourced	 pro-
ducts collated under the 4Es
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The various demand and supply side reforms instigated among 
the European countries and regions similarly influenced prescrib-
ing efficiency for the statins (Figure 2). The same categorization for 
efficiency has been used (Table 3), and again countries have been 
broken down into geography and approaches to the prescribing 
of generics.
In	Poland,	there	was	over	a	140-fold	increase	in	statin	utilization	
between 2002 and 2007 following their reimbursement, with overall 
a 4.5-fold difference between the rate of increase in utilization versus 
the rate of increase in reimbursed expenditure between 2001 and 
2007. This efficiency gain was helped by the instigation of reference 
pricing for the statins. Again, Serbia was excluded from Figure 2 with 
comprehensive data only recently becoming available.
FIGuRE 1 | Rate of increase in expenditure (local currency) versus the 
rate of increase in utilization (DDD based) for the PPIs principally from 
2007 versus 2001 among European countries (unless stated), with 
generic pricing approaches divided into three categories. Standard EU 
country abbreviations have been used. ES = Catalonia (2007 versus 2003), 
EE = 2007 versus 2004, HR = 2007 versus 2000, IT = 2008 versus 2006, 
NO = 2007 versus 2004, TR = 2009 versus 2007.
Table 3 | Principal measures used to evaluate changes in prescribing efficiency for both the PPIs and statins during the study years as well as 
categorize countries.
Objective Measure Efficiency criteria/comment
Assessment of overall The increase in utilization rates Three efficiency criteria 
prescribing efficiency versus the increase in reimbursed   No efficiency – rate of increase in expenditure exceeds utilization 
 expenditure over time*   Efficient countries – rate of increase in utilization more than 
double the rate of increase in expenditure
    Considerable efficiency – reimbursed expenditure decreasing over 
time despite increasing utilization. In the case of statins this also 
includes considerably increased utilization (over 350% during the 
study period) with only a limited increase in expenditure (20% or less)
Extent of potential savings from Overall utilization in 2007 (DDD/TID) compared Data treated with caution as different co-payment levels for 
increasing prescribing efficiency with overall expenditure (€/1000 inhabitants/year),  the PPIs and statins (Table A1 of Appendix) in addition to 
 with both measures adjusted for population sizes any co-payment for the package
*Generic PPIs and statins were often available in Central and Eastern European countries before 2001 distorting the figures in reality. The Republic of Ireland will not 
be included when assessing potential savings (Figures 3 and 4) as the GMS population has greater morbidity than the general population reflected in appreciably 
higher utilization of pharmaceuticals.
Those showing considerable efficiency, in addition to general 
efficiency, i.e., below the line drawn, are highlighted using the defi-
nitions in Table 3.
In	both	Lithuania	and	Poland,	there	was	approximately	a	twofold	
difference in the rate of increase in utilization (DDD basis) versus 
the	rate	of	increase	in	reimbursed	expenditure	for	the	PPIs	between	
2001 and 2007, e.g., in Lithuania utilization increased 10.8-fold 
between	2001	and	2007	and	Poland	over	150-fold	between	2002	
and 2007. This appreciable increase in utilization following reim-
bursement, which was considerably greater than seen in the other 
European countries, led to their exclusion from Figure 1. Serbia was 
also excluded from Figure 1 with comprehensive data only recently 
becoming	available,	and	after	the	availability	of	generic	PPIs.
FIGuRE 2 | Percentage change in utilization (DDDs) versus the 
percentage change in reimbursed expenditure (local currency) for the 
statins principally from 2001 to 2007 among European countries. The 
countries again divided into former Central and Eastern European countries 
(CEE) with the approaches to generic pricing divided into three categories. 
Standard EU country abbreviations have been used. ES = Catalonia (2007 
versus 2003), EE = 2007 versus 2004, HR = 2007 versus 2000, IT = 2008 
versus 2006, NO = 2007 versus 2004, TR = 2009 versus 2007.
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dIscussIon
Additional reforms are essential across Europe to continue funding 
increased volumes and new drugs without prohibitive increases in 
either taxes or health insurance premiums. As such, we consider 
the findings from this study help provide future direction to health 
authorities and health insurance agencies as they seek to instigate 
additional measures. This is despite the limitations of the study 
design, which are discussed later.
General findings from the study include more limited utilization, 
and	hence	expenditure,	of	the	PPIs	and	statins	among	Central	and	
Eastern European countries compared with Western European coun-
tries (Figures 3 and 4). This is principally due to prescribing restric-
tions and higher patient co-payments in these countries (Table A1 of 
Appendix). This endorses the need to document ongoing reforms when 
comparing utilization rates across countries otherwise there could be 
concerns with the accuracy of the data provided. Table A1 of Appendix 
also	demonstrates	that	the	“4	Es”	provides	a	methodology	for	health	
authorities and health insurance agencies to comprehensively categorize 
their current demand-side initiatives ready for comparisons.
More specific findings include the fact that both supply and 
demand-side reforms are essential to maximize prescribing effi-
ciency. The findings also demonstrate that the influence of the 
reforms	appears	to	be	additive,	with	“enforcement”	having	appreci-
able influence on subsequent utilization patterns.
Prescribing	 efficiency	 in	 Norway	 for	 the	 PPIs	 (Figure 1) is 
enhanced by its aggressive prescriptive pricing policy for generics, 
overcoming to some extent more limited demands side measures for 
the	PPIs	compared	with	Sweden	and	the	UK	(Table A1 of Appendix). 
The various pricing policies for generics in Austria, France and 
Portugal	also	helped	improve	prescribing	efficiency	with	for	instance	
the	PPIs	despite	limited	demand-side	measures	in	these	countries	for	
this class (Table A1 of Appendix). Overall though just concentrating 
on one aspect of reforms, i.e., either supply or demand-side measures 
but not both, will not help health authorities or health insurance 
agencies fully realize potential efficiency gains from the availability 
of generics. This is illustrated when comparing for instance pre-
scribing efficiency for the statins in Sweden and the UK (England 
and Scotland) versus Germany (Figures 2 and 4). In Germany in 
2007, there was very limited utilization of atorvastatin following the 
introduction of reference pricing for the class in 2003 at just 2% of 
overall statin utilization (Godman et al., 2009b) with rosuvastatin 
not available. This compares with 21 and 33% respectively on a DDD 
basis for the appreciably more expensive atorvastatin and rosuvasta-
tin in Sweden and England in 2007 (Godman et al., 2010c). However, 
comparative expenditure appears similar or greater in Germany 
due to higher expenditure/DDD for simvastatin (Figure 4). There 
are also differences in prescribing efficiency between Croatia and 
Finland even though there are high patient co-payment levels in 
both	countries.	Prescribing	efficiency	has	been	enhanced	in	Finland	
by	active	reforms	to	lower	generic	prices,	e.g.,	a	3-month’s	course	of	
simvastatin during early 2006 was €17 versus €127 in 2002 before 
the introduction of generic substitution (Martikainen et al., 2010), 
as well as measures restricting the prescribing of atorvastatin and 
rosuvastatin (Table A1 of Appendix).
The additive nature of the demand-side measures is illustrated by 
greater prescribing efficiency in Catalonia (Spain), Sweden and the 
UK with their multiple and intensive measures based on  education, 
The	differences	seen	in	prescribing	efficiency	for	the	PPIs	(Figure 1) 
translate into considerable differences in overall expenditure adjusted 
for the differences in population sizes, i.e., expenditure expressed in 
€/1000 inhabitants/year and utilization by DDDs/1000 inhabitants/
day (DDD/TID) by 2007 (Figure 3). The differences in geography and 
approaches to the prescribing of generics have again been highlighted. 
Expenditure	figures	for	the	PPIs	will	be	affected	by	whether	there	are	
high patient co-payment levels (Table A1 of Appendix).
The differences seen in the rates of prescribing efficiency for the 
statins between 2001 and 2007 among European countries (Figure 2) 
are again reflected in considerable differences in overall expenditure in 
2007 adjusted for population sizes (Figure 4). The differences in geog-
raphy and approaches to the prescribing of generics have again been 
highlighted, with overall expenditures again affected by whether there 
are high co-payment levels for the statins (Table A1 of Appendix).
FIGuRE 3 | utilization (DDD/TID) and overall expenditure (€/1000 
inhabitants/year) for PPIs among European countries in 2007 (Italy 2008, 
Serbia 2008). Standard EU country abbreviations have been used. 
ES = Catalonia. Republic of Ireland not included as the GMS population has 
greater morbidity than the general population.
FIGuRE 4 | utilization (DDD/TID) and overall expenditure (€/1000 
inhabitants/year) for the statins among European countries in 2007 
(Italy 2008, Serbia 2008). Standard EU country abbreviations have been 
used. ES = Catalonia. Republic of Ireland not included as the GMS population 
has greater morbidity than the general population.
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There have been concerns that extensive demand-side meas-
ures including prescribing restrictions can alter the quality of 
subsequent care (Fein, 2010). However, a recent ecological study 
demonstrated similar surrogate outcomes in patients with hyperc-
holesterolemia whether they were prescribed formulary drugs, i.e., 
generic simvastatin, or non-formulary drugs including atorvastatin 
(Norman et al., 2009).	Recent	studies	conducted	in	the	UK	have	also	
shown that patients can be successfully switched from atorvastatin 
to generic simvastatin without compromising care (Usher-Smith 
et al., 2008). Conserved resources can be re-directed to fund pro-
grams to improve compliance as well as fund increased volumes 
with the growing incidence of cardiovascular diseases. Compliance 
is a real concern in patients with chronic asymptomatic diseases 
(Cramer et al., 2008) rather than any minor differences in effec-
tiveness between the statins in clinical trials, which is not seen in 
practice (Usher-Smith et al., 2008; Norman et al., 2009).
We are also seeing countries learning from each other as resources 
pressures grow. This builds on earlier examples generally within 
healthcare (Toth, 2010), with some examples contained in Table 4.
As discussed, we accept there are limitations with the study 
design, which are summarized in Table 5. However, some of these 
issues are less important when comparing changes in utilization 
and/or expenditure as opposed to comparing absolute numbers.
As a result, some of the findings especially regarding expendi-
tures need to be treated with caution.
Never-the-less, we consider the findings will be of interest to 
health authorities and health insurance agencies as they plan future 
supply and demand-side measures to further improve their pre-
scribing efficiency. We also believe the findings will be of interest to 
pharmaceutical companies as they plan for the future, especially as 
health authorities and health insurance agencies become increas-
ingly proactive to conserve resources for existing products (Moon 
et al., 2010).
Ongoing initiatives to optimize the managed entry of new drugs 
will be discussed in future papers particularly as they underscore 
the notion that the funding of new premium priced products is an 
important challenge in Europe (Garattini et al., 2008).
engineering and economic initiatives (Table A1 of Appendix) com-
pared	with	France,	Portugal,	the	Republic	of	Ireland	and	Turkey	
(Figures 1 and 2) due generally to more limited demand-side meas-
ures in these countries (Table A1 of Appendix); although this is now 
changing in France (Sermet et al., 2010). These findings concerning 
the additive influence of demand-side measures endorse the results 
from previous studies which also showed that multiple interven-
tions appear more successful in changing prescribing behavior 
than single interventions (Bero et al., 1998; Barton, 2001; Grol 
and	Grimshaw,	2003;	Prosser	and	Walley,	2005).
Introducing prior authorization, or other similar enforcement 
schemes, also enhances prescribing efficiency, e.g., statins in Austria, 
Germany and Norway (Figure 2), coupled with reforms to lower 
generic prices (Table A1 of Appendix). This compares with a more 
limited	influence	on	prescribing	efficiency	for	the	PPIs	in	Austria	
with	just	“education”	and	“economic”	measures	in	the	absence	of	
“enforcement”	(Figure 1; Table A1 of Appendix). The improved 
efficiency	seen	with	introducing	“enforcement”	measures	for	the	
statins in these three countries appears similar to the combination 
of extensive educational, engineering and economic initiatives for 
the statins in for instance England and Sweden (Figure 2; Table A1 
of Appendix) along with measures to lower generic prices.
“Enforcement”	can	be	also	additive	and	introduced	at	any	stage	as	
seen in Austria where prescribing restrictions for atorvastatin built on 
existing educational and economic activities (Table A1 of Appendix; 
Godman et al., 2009c). This was also seen in Sweden where recent restric-
tions	on	Angiotensin	Receptor	Blockers	have	increased	their	prescribing	
second line building on existing educational, engineering, and economic 
initiatives among the counties (Wettermark et al., 2010a).
As a result of the differences in the nature and extent of demand-
side initiatives across these countries, there are appreciable dif-
ferences in overall prescribing efficiency between France, Ireland 
and	Portugal	when	compared	with	Catalonia	(Spain),	Sweden	and	
the UK (Figures 1 and 2), and when adjusted for population sizes 
(Figures 3 and 4).	Reimbursed	expenditure	is	also	high	in	Ireland	
in their selected GMS population at over €60,000/1000 inhabitants/
year	for	both	the	PPIs	and	statins.
Table 4 | Examples of countries learning from each other (Godman et al., 2008b, 2009a; Wettermark et al., 2008, 2010a; Barry et al., 2010; Martikainen 
et al., 2010; McGinn et al., 2010).
Measures Examples
Supply side – pricing examples Republic of Ireland introducing reference pricing for the molecule unless there are 
 concerns such as a narrow therapeutic window
 Health Insurance Fund in Lithuania actively considering reference pricing for the class
 Republic of Serbia recently introducing policies to further lower the price of generics
 The Office of Fair Trading in the UK proposing reference pricing for both the molecule and the class. 
 The latter building on the recent experiences in Sweden with proposed reference pricing for the PPIs
Demand-side initiatives Regions in Spain introducing prescribing targets linked with financial incentives
 Prescribing restrictions introduced for atorvastatin and rosuvastatin in Finland
 Compulsory INN prescribing in Lithuania unless prior approval granted
 The national reimbursement agency in Sweden introducing prescribing restrictions for ARBs and patent 
 protected statins to enhance prescribing efficiency compared with continuing with reference pricing (as 
 seen with the PPIs – Table 1) as more complex disease areas than excess acid in the stomach
 Primary Care Trusts in the UK instigating therapeutic substitution and prior approval schemes to 
 further enhance prescribing efficiency
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appendIx
Table A1 | Pricing approaches for generics and major demand-side measures principally for the PPIs and statins among the different European 
countries typically up to 2007 (Von Ferber et al., 1999; Schmacke and Lauterberg, 2002; Wessling and Lundin, 2006; Hyde, 2007; Magrini et al., 2007; 
Office of Fair Trading, 2007; Peura et al., 2007; Sakshaug et al., 2007; Fattore and Jommi, 2008; Festoy et al., 2008; Godman et al., 2008a,b, 2009b,c, 
2010a,b,c; Simoens, 2008a; Teixeira and Vieira, 2008; Wettermark et al., 2008, 2009a,b, 2010a; Eriksson and Lundin, 2009; Adamski et al., 2010; Barry 
et al., 2010; DoH, 2010; Martikainen et al., 2010; McGinn et al., 2010; Sermet et al., 2010; Stock et al., 2010).
Country Key supply and demand-side reforms
AT – Austria Generic pricing (mixed approach)
  Initially first generic 48% below originator, with originator mandated to lower its price by 30% for continued 
reimbursement; second generic 15% below the first to be reimbursed; third generic 10% lower than the second 
(overall 60% below pre-patent loss prices)
 Market forces after that with physicians incentivized to prescribe cheapest branded generics
Demand-side measures
 Education – includes guidance and benchmarking
  Economics – includes financial incentives for physicians to enhance efficient prescribing including the cheapest 
generic in the class
  Enforcement – Prescribing restrictions for both atorvastatin and rosuvastatin (prior approval scheme via the Chief 
Medical Officer of the patient’s social health insurance fund)
DE – Germany Generic pricing
 Market forces for generics along with reference pricing in the class (PPIs and statins)
Demand-side measures (variation among the States)
 Educational initiatives – include prescribing guidance, quality circles and web based training programs
  Economics – includes budgets, financial incentives linked with prescribing targets and patient co-payments for a 
more expensive molecule than the referenced priced product (molecule or class)
  Engineering – includes Disease Management programs, price: volume agreements, rebate contracts between 
pharmaceutical companies and Sickness Funds and prescribing targets
  Enforcement – Atorvastatin delisted from the normal reimbursement list in 2003 following the instigation of 
reference pricing for the statins (“Jumbo Class”)
EE – Estonia Generic pricing
 Third generic 43% below originator prices; market forces after that
Demand-side measures
 Education – prescribing information to physicians
 Economics includes co-payment for the PPIs and statins
  PPIs – 50% co-payment
   Statins – 10–25% co-payment, rosuvastatin 50% co-payment in patients with familial hypercholesterolemia (total 
cholesterol > 8 mmol/l) and following a CV event (total cholesterol > 4.5 mmol/l)
 Enforcement for the statins – reimbursement only for restricted indications otherwise 100% co-payment
ES – Spain and regions (Catalonia) Generic pricing
 Currently market forces driving down generic prices. This may change to a mixed approach
Demand-side measures (some variation among Autonomous Communities including Catalonia)
 Education – includes benchmarking, guidance and educational courses
 Economics – includes financial incentives for physicians to meet agreed prescribing targets
 Engineering – includes prescribing targets
  Enforcement – includes mandatory for pharmacists to dispense cheapest molecule if the prescribed product is more 
expensive than current reference price, which is usually a generic. This must be generic if the same price as the drug 
prescribed. No opportunity for patients to cover any additional costs themselves
FI – Finland Generic pricing
  Mixed approach to the pricing of generics. The price of the first generic has to be 40% lower than the price of the 
original product to be reimbursed
(continued)
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  Prices of subsequent generics must not be higher than the first generic to be reimbursed with market forces driving 
down prices with the introduction of generic substitution with the cheapest product from 2003. Substitution 
mandatory unless forbidden by the physician or patient; although there can be higher co-payments for more 
expensive products
Demand-side measures
  Education – clinical guidelines as well as EBM initiatives to enhance the quality of prescribing. However, no 
prescribing targets as seen in a number of other European countries
 Economics – principally via patient co-payments
   2001: PPIs – €8.41/purchase plus 50% co-payment (Basic Refund Category), similarly for statins for most patients. 
Patients with familial hypercholesterolemia or coronary artery disease entitled to lower co-payment at €4.20/
purchase and 25% co-payment
   2007: PPIs 58% co-payment; similarly for the statins unless familial hypercholesterolemia or coronary artery 
disease entitlement where only 28% co-payment (applied to 15% of statin users)
  Enforcement – in 2006 atorvastatin and rosuvastatin restricted to second line as appreciably more expensive than 
other statins with limited additional benefit (restriction for atorvastatin subsequently abolished in 2009 with the 
availability of generic atorvastatin and reference pricing for the molecule) 
FR – France Generic pricing
  Prescriptive pricing for generics with the first generic priced 55% below the originator for reimbursement. Prices 
further reduced by 7% after 18 months. 
Demand-side measures
  Education – includes campaigns to enhance the prescribing and dispensing of generics through for instance 
benchmarking of physician prescribing and campaigns to allay fears regarding generics
 Economics
   Incentives to physicians, patients and pharmacists to enhance the prescribing and dispensing of generics versus 
originators including encouraging physicians to prescribe by INN name
  Co-payments – working out on average 20% for PPIs and statins (when factoring in patients with long term illness)
  Engineering  
  Price: volume agreements for existing compounds)
   Campaigns from 2009 to enhance the prescribing of generics in a class through prescribing targets linked 
with financial incentives (CAPI – Contrats d’amélioration des pratiques individuelles) prescribing targets 
(engineering) 
GB – England Generic pricing
  Market forces with transparency in pricing of generics coupled with high INN prescribing. This has typically resulted 
in low prices for generics
Demand-side measures (national and local with some variation among Primary Care Trusts)
  Education – includes for instance national and local prescribing guidance (e.g., NICE, British National Formulary and 
PCT prescribing guidance), benchmarking and academic detailing
 Economics – budget devolution, Practice Based Commissioning and physician financial incentives
  Engineering – includes Better Care, Better Value indicators for low cost PPIs and statins as well as prescribing support 
programs encouraging active therapeutic substitution. In addition, proactively managing the introduction of new 
generics through encouraging the prescribing of patent protected products in a class that will soon lose their patent 
ahead of other single sourced products in a class
GB – Scotland  As for England 
 However, budgets not devolved locally (GPs responsible for their drug budgets but not accountable)
HR – (Croatia) Generic pricing
  Mixed approach. The first generic should not be priced higher than 70% of the originator pre-patent price to be 
reimbursed (originator price dropping by at least 10%)
  Second generic – a maximum of 90% of the price of the first generic for reimbursement; third generic maximum 
price of 90% of the second with market forces further lowering prices with patients paying the difference for a more 
expensive molecule than the current reference
Country Key supply and demand-side reforms
Table A1 | (continued)
(continued)
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Demand-side measures
 Education – National formulary providing prescribing guidance, with only a limited number of treatment guidelines
 Engineering includes – price: volume agreements – although applies to new drugs
  Economics includes higher co-payments for more expensive products that the reference molecule. It also includes 
co-payments for the statins and PPIs
   For the statins – in 2003 – 25% co-payment for secondary prevention in patients with ischemic heart disease or 
cerebrovascular disease and with patients with diabetes with a TC > 5 mmol/l; 75% for patients for primary 
prevention whose 10-year chance of CHD >20% or will be at the age of 60. Reimbursement only if treatment 
initiated for patients <70 years
   In 2006, similar to 2003 for secondary prevention (25%). Primary prevention includes TC > 7 mmol/l after 3 months 
diet (75% co-payment).
   In 2008 (outside study period), no co-payment for patients meeting criteria for primary and secondary  
prevention – co-payment only if they wish originator atorvastatin
   For the PPIs – typically no co-payment in patients where H2 blockers no longer working for esophageal reflux, 
alternatively for Zollinger Elisonov syndrome or eradication of Helicobacter pylori; otherwise 100% co-payment
 Enforcement – Access to patient history to check criteria for reimbursement, e.g., statins and PPIs
IE – Republic of Ireland Generic pricing
  Overall mixed approach with the recent introduction of a two step price reduction process for patent expired 
products – 20% reduction on patent expiry  (in 2007) followed by a further 15% reduction after 22 months (in 2011) 
(expected to realise €275 mn by 2011)
Demand-side measures
 Limited demand-side reforms to date to encourage the prescribing of generic drugs first line
IT – Italy Generic pricing
 The first generic 20% below the originator; market forces after that
Demand-side measures (Variation among health authorities)
 Educational initiatives – guidelines, academic detailing and benchmarking
  Economics – financial incentives for GPs, additional patient co-payment for more expensive molecules than the 
reference molecule
 Engineering – capping ambulatory care budgets
 Enforcement – prescribing restrictions for certain indications
LT – Lithuania Generic pricing
 Currently first generic 30% below originator, second and third generics 10% below this; market forces after that
Demand-side measures
  Education – some guidelines in place to encourage rational use of medicines but not obligatory. In addition auditing of 
prescribing habits with possible financial penalties for excessive costs
 Economics – includes co-payments for PPIs and statins, as well as possible financial penalties for physicians (above)
  PPIs – 50%+ for majority of indications
   Statins - Only 20% co-payment. Initially statins only reimbursed for secondary prevention (post event) and for only 
6 months. Reimbursement restrictions now lifted for generic statins
  Engineering – includes obligatory INN prescribing unless concerns ( compulsory from 2010 unless prior authorization 
from Hospital or Polyclinic Therapeutic Committee)
  Enforcement (statins only) – reimbursement only post AMI and only for 6 months (reimbursement restrictions now 
lifted for generic statins). In addition, the first prescription must be written by a cardiologist otherwise 100% 
co-payment
NO – Norway Generic pricing
 Aggressive prescriptive pricing policy for generics with high volume generics 85% below originator prices
Demand-side measures
 Limited educational initiatives during the study period
Country Key supply and demand-side reforms
Table A1 | (continued)
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 Enforcement
   PPIs – prescribing of esomeprazole restricted in 2007. Specialists though required to verify the diagnosis and 
recommend therapy
   Statins – atorvastatin restricted from 2005 (rosuvastatin not reimbursed) with physicians encouraged to actively 
substitute patients currently prescribed atorvastatin. Spot checks undertaken amongst physicians if abuse suspected
PO – Poland Generic pricing
  Market forces driving down generic prices. In addition reference pricing in a class and across therapeutic groups (ATC 
Levels 3 and 4)
Demand-side measures
 Education – generally limited educational interventions; although variable among the regions
  Economics – includes co-payment for the indication as well as additional co-payment for a more expensive brand than 
the reference product (molecule, class, or therapeutic area)
  PPIs – 30% (apart from esomeprazole which is not reimbursed)
  Statins – 30% (apart from rosuvastatin which is not reimbursed)
  Enforcement – Pharmacists are obliged to inform patients about generic products if they have the same active ingredient, 
dosage, package and route of administration as the prescribed product but cheaper (as branded generics in Poland)
PT – Portugal Generic pricing
  Mixed approach to the pricing of generics with the first generic priced at least 35% below the originator; this reduces 
to 20% if the originator price is below €10/pack. Further price reductions in 2005, 2007, and 2008
 2005 and 2007 – 6% price reduction for all reimbursed medicines
  After March 2007 also annual price reductions for generics depending on the market share of each active substance 
(5, 9, or 12%)
 2008 – further 30% price reduction for generic medicines
  2010 – further changes to try and reduce prices within homogeneous groups, i.e., same active substance, 
pharmaceutical form, strength and route of administration
  In addition, ongoing activities by pharmaceutical companies to suspend market authorization for generics as a 
counter measure. The official database from Infarmed (July 2010) includes 17 active substances and more than 500 
medicines (packages) where marketing authorization has been suspended
Demand-side measures
  Education – includes guidelines (although not mandatory) and campaigns promoting generics. The latter include 
patient campaigns via TV, radio, leaflets in hospitals and community pharmacies as well as physicians updated every 
quarter by INFARMED of available generics
  Economics – includes establishing a Reference Price System (RPS) in 2002 defining a fixed amount paid by the NHS 
for homogeneous groups. In May 2010 no co-payment for pensioners (100% reimbursement) whose income is 
below the national minimum wage (the so called Special Regime). In June 2010, new legislation reimbursing 100% 
only the five cheapest medicines in a homogeneous group
  Engineering – Agreements between the Portuguese Pharmaceutical Industry (represented by APIFARMA) and the 
Ministry of Health with the objective of limiting the growth in the NHS expenditure on pharmaceuticals
  Enforcement – includes since 2002 an obligation for physicians to prescribe by INN for medicines with approved 
generics; however they can prohibit substitution where patient concerns. Pharmacists are allowed to substitute 
generics where physicians have prescribed by INN name and have not prohibited substitution, and should also inform 
patients about generic prices versus originators (however no financial incentives for this)
RS – Serbia Generic Pricing
  Mixed approach with the first generic priced at least a minimum of 80% of average current prices in three reference 
countries (Slovenia, Croatia and Italy)
  Subsequent generics should be priced similar or lower to gain market share with the lowest price product 
establishing the reference price for the molecule
  In addition, to help further lower prices originator and generic drugs must now have the same price for 
reimbursement with no opportunity for patients to pay an additional co-payment for a more expensive product
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Demand-side measures
  Economics - Patients initially required to pay an additional co-pay for a more expensive product than the current 
reference price (same INN name - ATC Level 5) - now changing (above). Prescribing efficiency helped by early 
availability of generics – similar to the situation in Poland (above)
  Enforcement – Prior authorization schemes in place for selected premium priced drugs based on step therapy 
approaches
SE – Sweden Generic pricing
 Market forces driving down prices with compulsory generic substitution
Demand-side measures (some variation among the Counties)
  Education – includes a range of measures incorporating prescribing guidance and guidelines, routine benchmarking 
against colleagues and against recommended drugs, as well as electronic prescribing support systems
 Economics – includes devolved budgets and financial incentives
 Engineering – includes prescribing targets such as % of statins as generic statins
 Enforcement – includes prescribing restrictions for rosuvastatin (since launch) and atorvastatin (post 2007)
SI – Slovenia Generic pricing
 First generic no higher than an average of 82% of prices in Austria, France and Germany; market forces after that
Demand-side measures
  Education – includes the Health Insurance Institute organizing therapeutic meetings and undertaking audits of 
prescribing habits
 Economics – includes additional co-payments for more expensive compounds than the reference product
  Enforcement – includes prescribing restrictions for certain drugs based on their more limited value versus current 
standards
TR – Turkey Generic pricing
  The first generic must be priced no higher than 66% of the originator’s pre-patent loss price; subsequently subject to 
a 11% price reduction
Demand-side measures
 Education – limited activities to date
 Enforcement – some prescribing restrictions but not applying to PPIs or statins
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